Very interesting data were presented on the use of circulating DNA evaluation in a very rare disease. I mean, in the RAMP 201 trial, we saw that the evaluation of ctDNA did not correlate with the molecular analysis on the tissue. And this was very, very, I mean, it was just a pity because I believe that maybe it would be useful for our patients. Also, there was presented some interesting data on the ADCs, mainly sacituzumab, with the increased risk of cataract due to the use of the steroids to prevent the toxicity of this kind of drugs...
Very interesting data were presented on the use of circulating DNA evaluation in a very rare disease. I mean, in the RAMP 201 trial, we saw that the evaluation of ctDNA did not correlate with the molecular analysis on the tissue. And this was very, very, I mean, it was just a pity because I believe that maybe it would be useful for our patients. Also, there was presented some interesting data on the ADCs, mainly sacituzumab, with the increased risk of cataract due to the use of the steroids to prevent the toxicity of this kind of drugs. So it was quite interesting as a congress.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
